Sitari Pharmaceuticals

Drugs targeting the Transglutaminase 2 (TG2) pathway to treat multiple disease indications, with an initial focus in celiac disease.

Get a Demo and See the Full Profile

Get a demo today to see profiles of Sitari Pharmaceuticals plus 5767 other startups.

Get A Demo

Learn More About Sitari Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups


Companies We Work With